

# FOR HEALTHCARE PROFESSIONALS

Earn free CME/CE credit for your participation: [www.LLS.org/CE](http://www.LLS.org/CE)



## FREE CME/CE ROUNDS AND WEBINARS at [www.LLS.org/CE](http://www.LLS.org/CE)

### Upcoming In-Person Regional Rounds:

- Myeloma Rounds: **Durham, NC March 4, 2025, Evening**
- Myeloma Rounds: **Seattle, WA March 20, 2025, Evening**
- Myeloma Rounds: **San Francisco, CA March 22, 2025, Morning**
- Myeloproliferative Neoplasms (MPNs) Rounds: **Chicago, IL April 23, 2025, Evening**
- Acute Leukemia Rounds: **Philadelphia, PA May 22, 2025, Evening**

### Webinars:

- Bispecific Therapy: Advancing Patient Care through Targeted Treatment **Live March 11, 2025, 5:00 PM ET**
- **Coming soon:** Blood Cancer 101 for Healthcare Professionals – in Spanish
- Hematopoietic Cell Transplantation as Treatment for Blood Cancers: The Team Approach
- Chronic Myeloid Leukemia: Diagnosis, Treatment, and Side Effect Management
- Highlights and Key Updates from Myeloma Rounds
- Treating Myelodysplastic Syndromes Transformation to Acute Myeloid Leukemia
- Clinician Strategies and Resources: Caring for AYAs Transitioning to Survivorship
- Caring for Patients with Blood Cancer in the Hispanic Community



## Free Healthcare Professional Resources

For you and your patients

### FOR YOU



Continuing education for physicians, nurses, social workers and other HCPs

- In-person activities and online webinars: [www.LLS.org/CE](http://www.LLS.org/CE)

Resources and publications

- [www.LLS.org/HCPbooklets](http://www.LLS.org/HCPbooklets)

Tune into *Treating Blood Cancers* - podcasts for HCPs

- On a variety of blood cancer topics: [www.LLS.org/HCPpodcast](http://www.LLS.org/HCPpodcast)

Staying Connected: Facilitating the Learning Experience During & After Cancer Treatment

- A CE activity for school personnel on the medical, psychosocial, and educational challenges children and families face during and after treatment: [www.LLS.org/StayingConnected](http://www.LLS.org/StayingConnected)

Blood cancer research and research grant opportunities: largest nonprofit funder of leading-edge research for every type of blood cancer - [www.LLS.org/Research](http://www.LLS.org/Research)

- Research Grant programs - support scientific studies at academic centers throughout the world.
- Therapy Acceleration Program® (TAP) - strategic venture philanthropy initiative; builds business alliances and collaborations with biotechnology companies.
- Children's Initiative - taking on children's cancer through Research, Patient Education and Support and Policy and Advocacy: [www.LLS.org/Childrens-Initiative](http://www.LLS.org/Childrens-Initiative)

## TREATING BLOOD CANCERS

LLS Podcast Series for Professionals

Tune in to learn more about Treating Blood Cancers. [www.LLS.org/HCPpodcast](http://www.LLS.org/HCPpodcast)

### Highlighted Episodes:

- Exploring Cutaneous T-Cell Lymphoma
- Highlights from Attending ASH 2024
- Bispecifics in Lymphoma
- Mental Health in Cancer Survivorship
- What's New in CLL?
- Decoding Medicare for HCPs
- Addressing Barriers & Disparities for Hispanic/Latinx Patients



CONTINUING EDUCATION (CE) PROGRAMS

[www.LLS.org/CE](http://www.LLS.org/CE)



CONTINUING MEDICAL EDUCATION (CME) PROGRAMS

[www.LLS.org/CME](http://www.LLS.org/CME)



HCP PODCAST

[www.LLS.org/HCPpodcast](http://www.LLS.org/HCPpodcast)



NON-ACCREDITED VIDEOS

[www.LLS.org/HCPvideos](http://www.LLS.org/HCPvideos)

# FOR HEALTHCARE PROFESSIONALS

Earn free CME/CE credit for your participation: [www.LLS.org/CE](http://www.LLS.org/CE)



## FACT SHEETS FOR HEALTHCARE PROFESSIONALS

**LEUKEMIA & LYMPHOMA SOCIETY**

**Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy**

**HEALTHCARE PROFESSIONALS**  
No. 1 in a series providing the latest information

**Introduction**  
Autologous chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematologic malignancies has generated intense interest from patients, families and healthcare providers. Clinical trials are underway for multiple B-cell malignancies, including B-cell lymphomas (B-ALL), non-Hodgkin lymphoma (NHL), indolent mantle cell lymphoma (MCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL), as well as myeloid leukemias (AML) and MDS. The first 2 autologous CAR T and Drexel Administration to, and subsequent release of A measure of these and other technology and medical team will explain the rationale behind that have emerged, provide p-implications of this therapy in

**Highlights**

- CAR T-cell therapy represents a novel and potentially transformative approach to cancer treatment
- CAR T-cell therapy involves engineering cells with the ability to recognize and kill cancer cells
- CAR T-cell therapy is currently approved for the treatment of B-cell lymphoma and multiple myeloma
- CAR T-cell therapy is currently approved for the treatment of acute myeloid leukemia and myelodysplastic syndrome
- CAR T-cell therapy is currently approved for the treatment of acute myeloid leukemia and myelodysplastic syndrome

www.LLS.org • Information Specialist: 800.955.4572

**LEUKEMIA & LYMPHOMA SOCIETY**

**Facts About Lymphoma**

**HEALTHCARE PROFESSIONALS**  
No. 1 in a series providing the latest information

**Introduction**  
Lymphoma is a group of blood cancers that affect the lymphatic system, which is part of the immune system. Lymphoma is the most common type of cancer in children and the second most common type of cancer in young adults. Lymphoma is a group of blood cancers that affect the lymphatic system, which is part of the immune system. Lymphoma is the most common type of cancer in children and the second most common type of cancer in young adults.

**Highlights**

- Lymphoma is a group of blood cancers that affect the lymphatic system, which is part of the immune system.
- Lymphoma is the most common type of cancer in children and the second most common type of cancer in young adults.
- Lymphoma is a group of blood cancers that affect the lymphatic system, which is part of the immune system.
- Lymphoma is the most common type of cancer in children and the second most common type of cancer in young adults.

www.LLS.org • Information Specialist: 800.955.4572

**LEUKEMIA & LYMPHOMA SOCIETY**

**Facts About Chronic Lymphocytic Leukemia (CLL)**

**HEALTHCARE PROFESSIONALS**  
No. 1 in a series providing the latest information

**Introduction**  
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the lymphatic system. It is the most common type of leukemia in older adults. CLL is a type of cancer that affects the lymphatic system. It is the most common type of leukemia in older adults.

**Highlights**

- Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the lymphatic system.
- CLL is the most common type of leukemia in older adults.
- Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the lymphatic system.
- CLL is the most common type of leukemia in older adults.

www.LLS.org • Information Specialist: 800.955.4572

**LEUKEMIA & LYMPHOMA SOCIETY**

**Food Insecurity**

**HEALTHCARE PROFESSIONALS**  
No. 1 in a series providing the latest information

**Introduction**  
Food insecurity is a household-level economic and social condition of limited or uncertain access to adequate food. It is a household-level economic and social condition of limited or uncertain access to adequate food. It is a household-level economic and social condition of limited or uncertain access to adequate food.

**Highlights**

- Food insecurity is a household-level economic and social condition of limited or uncertain access to adequate food.
- Food insecurity is a household-level economic and social condition of limited or uncertain access to adequate food.
- Food insecurity is a household-level economic and social condition of limited or uncertain access to adequate food.
- Food insecurity is a household-level economic and social condition of limited or uncertain access to adequate food.

www.LLS.org • Information Specialist: 800.955.4572

**LEUKEMIA & LYMPHOMA SOCIETY**

**Facts About Facilitating Optimal Survivorship Care for Blood Cancer Survivors**

**HEALTHCARE PROFESSIONALS**  
No. 12 in a series providing the latest information

**Introduction**  
Transitioning to life beyond active treatment can be challenging for blood cancer survivors. All survivors in remission, or those whose disease has been detected, have an adjustment period. Many experience life-long challenges because of their disease and treatment. Additionally, some survivors may be managed with active surveillance and not offered active treatment right away. These survivors must adjust to the uncertainty of living with chronic cancer. Some may be in remission, but have a recurrence or progression of disease, and may have to undergo additional treatment.

**Highlights**

- Transitioning to life beyond active treatment can be challenging for blood cancer survivors.
- All survivors in remission, or those whose disease has been detected, have an adjustment period.
- Many experience life-long challenges because of their disease and treatment.
- Additionally, some survivors may be managed with active surveillance and not offered active treatment right away.
- These survivors must adjust to the uncertainty of living with chronic cancer.
- Some may be in remission, but have a recurrence or progression of disease, and may have to undergo additional treatment.

www.LLS.org • Information Specialist: 800.955.4572

**LEUKEMIA & LYMPHOMA SOCIETY**

**Facts About Biomarker Testing**

**HEALTHCARE PROFESSIONALS**  
No. 4 in a series providing the latest information

**Introduction**  
Cancer therapies have always leveraged the differences between normal and neoplastic cells, and over recent years our understanding of precisely what is different has expanded exponentially. A DNA sequencing technology has uncovered subtle variations in the genomes of cancer cells, revealing the underlying causes of cancer. It is challenging to keep pace with the extremely rapid development of newly identified targets or indications for approved therapies. There are access and reimbursement difficulties, particularly for targeted therapies not FDA-approved for a particular malignancy that may harbor a druggable alteration. Finally, patients need to be educated about molecular profiling in order to better inform their decision-making and allow them to be fully engaged partners in their care.

**Highlights**

- The goal of molecular profiling is to identify biomarkers associated with malignancies that can serve as therapeutic targets, inform diagnosis or prognosis, or guide response to therapy.
- Standard techniques such as fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and flow cytometry have been used for years to investigate hematologic malignancies. These techniques are limited by low resolution, and they can miss genomic-wide changes.
- Chromosomal microarrays (CMAs) enable whole genome "molecular karyotyping" in a single assay that does not require viable cells.
- CMAs have become routine for identifying copy number losses or gains of whole or segmental chromosomes.
- Next generation sequencing (NGS) technologies have allowed the detection of multiple DNA alterations across multiple genes.
- Targeted mutation panels sequence early genes suspected or known to be associated with a malignancy. There are many commercially available gene panels for hematologic malignancies.
- Research is emerging to assist clinicians in identifying the right test for the right patient at the right time.
- Molecular tumor boards and online resources are available to assist in the interpretation of data generated from molecular investigations of hematologic malignancies.

www.LLS.org • Information Specialist: 800.955.4572

To access booklets, palm cards and fact sheets, visit: [www.LLS.org/Booklets](http://www.LLS.org/Booklets)

## ONE-ON-ONE SERVICES FOR YOUR PATIENTS AND YOU

### CLINICAL TRIAL SUPPORT CENTER

Work one-on-one with an LLS Clinical Trial Nurse Navigator who can assist your patients or provide you with information on clinical trials and personally assist your patients throughout the entire clinical-trial process. To refer a patient visit:

[www.LLS.org/CTSC](http://www.LLS.org/CTSC)

### INFORMATION RESOURCE CENTER

Speak one-on-one with an Information Specialist who can assist your patients or provide you with information on cancer treatment, financial and social challenges and give accurate, up-to-date disease, treatment and support information. Our Information Specialists are highly trained oncology social workers and nurses. Bilingual specialists and interpretation services are available.

[www.LLS.org/IRC](http://www.LLS.org/IRC) Or call 800-955-4572

### NUTRITION CONSULTATIONS

LLS provides Nutrition Education Services to patients and caregivers of all cancer types. To schedule a free consultation, visit:

[www.LLS.org/Nutrition](http://www.LLS.org/Nutrition) Or call 877-467-1936

Our registered dietitians have expertise in oncology nutrition.



**LEUKEMIA & LYMPHOMA SOCIETY**

**LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS**

**YOUR FUTURE IS NOW**

Scholarship For Your Patients  
Visit [www.LLS.org/Scholarship](http://www.LLS.org/Scholarship)  
to sign up for updates on important application dates.

For personalized disease, treatment or support information, please contact an

LLS Information Specialist at 800.955.4572 or [www.LLS.org/ContactUs](http://www.LLS.org/ContactUs)